Abstract 1152
Background
This study was carried out as randomized-controlled, longitudinal interventional to determine whether there was a difference between the mean scores of compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) after applying the short-term and long-term ‘Compassion Fatigue Resiliency Program’ for nurses working in the field of oncology-hematology.
Methods
The sample of the study consisted of oncology-hematology nurses working in two private hospitals, one university hospital. Hospitals were randomly assigned to experiment I (n:34), experiment II (n: 49) and control groups (n: 42). Short-term (two days, five hours per day) program implemented to experiment I, long-term (five weeks, 2 hours a week) program implemented to experiment II and no any intervention implemented to control group. Measurements were made pre-intervention, post-intervention, third month, sixth month and first year. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Primary research hypotheses were tested with multilevel models (MLM).
Results
There was no statistically significant difference between the mean scores of CF, BO, PS and PR of the nurses in the short-term, long-term and control groups. The mean compassion satisfaction score of the nurses in the short-term and long-term education group was statistically significantly higher than in the control group. The mean CS scores of the nurses in both the short and long-term education groups were statistically significantly higher in the sixth month and first year follow-up measurements than in the pre-intervention period.
Conclusions
In this study, considering the effects of long-term and short-term education on CF, BO, CS, perceived stress and PR of nurses, it can be said that these two educations have the same effect on CS. It is the first study with randomized-controlled method, including the follow-up of up to a year. Doing new studies that are revealing the effect of this education can be suggested.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract